Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The **UL42/UL30 protein-protein interface** refers to the molecular interaction between the **UL42 processivity factor** and the **UL30 DNA polymerase catalytic subunit** of herpes simplex virus type 1. UL30 provides DNA polymerase and exonuclease activities, while UL42 enhances processivity by binding both UL30 (primarily via its C-terminus) and DNA. The interaction occurs through a flexible contact region, mainly at UL30’s C-terminal segment and a connector loop within UL42, involving salt bridges and positively charged surfaces that tether DNA and promote long-chain synthesis. Disruption of this interface prevents the formation of a fully processive viral polymerase, critically impairing viral DNA replication and replication origin usage. Structural studies reveal that UL42 is a monomer with a classic family B polymerase fold and that it mediates nuclear import of the holoenzyme via a bipartite nuclear localization signal (NLS). Targeting the UL42–UL30 interface is considered a promising antiviral strategy to inhibit HSV infections, and its specificity for the viral complex presents a lower risk of host toxicity
Potential interface inhibitors would block the physical association between UL42 and UL30, preventing formation of a processive viral DNA polymerase holoenzyme and thereby inhibiting viral replication
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Herpes simplex virus DNA polymerase UL42–UL30 protein-protein interface (UL42–UL30 interface).